What question did this study set out to answer?

To review the regulation and post-translational modifications of CD36 and evaluate its dual roles and therapeutic viability across distinct cardiovascular pathologies.

October 29, 2020Cardiovascular ResearchOpen Access

The role of CD36 in cardiovascular disease

View Full Paper

Ask AI

Bookmark

Why the study?

CD36 is closely associated with the progression of cardiovascular diseases and may represent a new therapeutic target.

Key Points

To review the regulation and post-translational modifications of CD36 and evaluate its dual roles and therapeutic viability across distinct cardiovascular pathologies.
Synthesized evidence on post-translational modifications regulating CD36 maturation and trafficking, including phosphorylation, ubiquitination, glycosylation, and palmitoylation.
Evaluated preclinical models of ischaemia-reperfusion injury, pressure overload hypertrophy, diabetic cardiomyopathy, and atherosclerosis displaying altered CD36 expression.
CD36 expression decreases during ischaemia-reperfusion injury and pressure overload hypertrophy, and overexpression of CD36 prevents ischaemia-reperfusion damage.
CD36 expression increases in diabetic cardiomyopathy and atherosclerosis, and CD36 deficiency significantly alleviates pathology in both disorders.

Design

Review

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Should not yet change practice in cardiomyopathy or atherosclerosis; leaves open CD36 as a target pending prospective trials.

Cite This Study

Shu et al. (2020) studied this question.

synapsesocial.com/papers/69fd29dc30a474415f89e2d2 https://doi.org/10.1093/cvr/cvaa319

View Full Paper

Ask AI

Bookmark

The role of CD36 in cardiovascular disease

Key Points

Discussion

Implication

Cite This Study

The role of CD36 in cardiovascular disease

Key Points

Discussion

Implication

Cite This Study

Also Consider

Also Consider